Serum peptidomic profiling identifies a minimal residual disease detection and prognostic biomarker for patients with acute leukemia

Oncology Letters

Volumn 6, Issue 5, 2013, Pages 1453-1460

  Song, Wei ^a   Wang, Na ^b   Li, Wei ^a   Wang, Guanjun ^a   Hu, Jifan ^a,c   He, Kun ^b   Li, Yan ^a   Meng, Ying ^a   Chen, Naifei ^a   Wang, Shaoxin ^b   Hu, Lingyun ^b   Xu, Bin ^b   Wang, Jie ^b   Li, Ailing ^b   Cui, Jiuwei ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b NATIONAL CENTER OF BIOMEDICAL ANALYSIS   (China)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute leukemia; Mass spectrum; Minimal residual disease; Peptide pattern

Indexed keywords

BIOLOGICAL MARKER; PEPTIDE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; KARYOTYPE; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMAL RESIDUAL DISEASE; PATTERN RECOGNITION; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; SUPPORT VECTOR MACHINE;

EID: 84884490454     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1574     Document Type: Article

References (26)

1. Falini B, Tiacci E, Martelli MP, Ascani S and Pileri SA: Acute myeloid leukemia (AML) and related precursor neoplasms. In: WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, SteinH, et al (eds): 4th edition. IARC, Lyon, France, pp109-147, 2008.
2. Pui CH, Relling MV and Downing JR: Acute lymphoblastic leukemia, N Engl J Med 350: 1535-1548, 2004.
3. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, BeranM, et al: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia, J Clin Oncol18: 547-561, 2000.
4. Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, et al: Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL0288 randomized study. Blood 99: 863-871, 2002.
5. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, RoweJM, Paietta E, et al: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management to acute myeloid leukemia in first remission. N Engl J Med 339: 1649-1656, 1998.
6. Dworzak MN, Fröschl G, Printz D, Mann G, Pötschger U, Mühlegger N, et al; Austrian Berlin-Frankfurt-Münster Study Group: Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 99: 1952-1958, 2002.
7. Mortuza FY, Papaioannou M, Moreira IM, Coyle LA, GameiroP, Gandini D, et al: Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 20: 1094-1104, 2002.
8. Campana D: Determination of minimal residual disease in leukemia patients. Br. J. Haematol 121: 823-838, 2003.
9. San Miguel JF, Vidriales MB, López-Berges C, Díaz-MediavillaJ, Gutiérrez N, Cañizo C, et al: Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood98: 1746-1751, 2001.
10. Guerrasio A, Pilatrino C, De Micheli D, Cilloni D, Serra A, Gottardi E, et al: Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 16: 1176-1181, 2002.
11. van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352: 1731-1738, 1998.
12. Schmidt HH, Strehl S, Thaler D, Strunk D, Sill H, Linkesch W, et al: RT-PCR and FISH analysis of acute myeloid leukemia with t(8;21)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implications. Leukemia18: 1115-1121, 2004.
13. Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, FelixK, Conrad T, Witzigmann H, Weimann A, Schütte C, HaussJ, Büchler M and Thiery J. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer. Clin Cancer Res 15: 3812-3819, 2009.
14. Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR and Herndon JE 2nd: Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 25: 5578-5583, 2007.
15. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al: Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14: 1065-1072, 2008.
16. Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, et al: Functional proteomic profiling of AML predicts response and survival. Blood 113: 154-164, 2009.
17. Cui JW, Li WH, Wang J, Li AL, Li HY, Wang HX, et al: Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol Cell Proteomics 4: 1718-1724, 2005.
18. Liang T, Wang N, Li W, Li A, Wang J, Cui J, et al: Identification of complement C3f-desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment. Proteomics10: 90-98, 2010.
19. Cao Y, Wang N, Ying X, Li A, Wang H, Zhang X and Li W: BioSunMS: a plug-in-based software for the management of patients information and the analysis of peptide profiles from mass spectrometry. BMC Med Inform Decis Mak 9: 13, 2009.
20. Ng KL and Mishra SK: De novo SVM classification of precursor microRNAs from genomic pseudo hairpins using global and intrinsic folding measures. Bioinformatics 23: 1321-1330, 2007.
21. Licastro F, Pedrini S, Ferri C, Casadei V, Govoni M, Pession A, etal: Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann Neurol 48: 388-391, 2000.
22. Bird PI: Regulation of pro-apoptotic leucocyte granule serine proteinases by intracellular serpins. Immunol. Cell Biol 77: 47-57, 1999.
23. Kloth JN, Gorter A, Fleuren GJ, Oosting J, Uljee S, ter HaarN, et al: Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. J Pathol 215: 222-230, 2008.
24. Lai ML, Rizzo N, Liguori C, Zucca G and Faa G: Alpha-1-antichymotrypsin immunoreactivity in papillary carcinoma of the thyroid gland. Histopathology 33: 332-336, 1998.
25. Estellés A, Gilabert J, Grancha S, Yamamoto K, Thinnes T, España F, et al: Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. Thromb Haemost 79: 500-508, 1998.
26. Wang Y, Jiang H, Dai D, Su M, Martinka M, Brasher P, etal: Alpha 1 antichymotrypsin is aberrantly expressed during melanoma progression and predicts poor survival for patients with metastatic melanoma. Pigment Cell Melanoma Res 23: 575-578, 2010.